Abstract: The invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to 19, 21 to 25, 27 to 28, 35 to 37, 39, 41, 43 to 44, 46 to 47, 49 to 50, 52 to 53, 55 to 58, 63 to 64, 66, 68 to 82, 84 to 85, and 87 to 98 of SEQ ID NO: 1; characterised in that said polypeptide comprises one or more mutations relative to SEQ ID NO: 1 selected from the group consisting of: T51L, T51V, M65V, N32G, A59I, L38A, V20I, A40I, L38V, A12I, A12V, I16L, V20L, Q26E, E29M, T31K, N32D, N32H, T34V, T34R, T34D, T34P, A40V, Q42D, T45I, T45V, V48E, V48G, V48A, T51F, T51A, A59L, L67I, (V20I, L38A), (V20L, L38A), (V20I, L38V), (V20L, L38V), (E29K, K30E, E33K), (Y54D, T83D, Q86E), (A59L, G60N, D61G, N62K), (A59V, D61N, N62K), (G60N, D61G, N62K), (G60N, ?D61, N62G), ?D61, (A59L, G60N, ?D61, N62G), (A59V, G60N, D61G, N62K), (A59I, G60N, D61G, N62K), (A59I, G60N, ?D61, N62G), (A59V, G60N, ?D61, N62G), (A59V, ?D61), (G60P, ?D61, N62P),

Abstract: Disclosed herein are therapeutic conjugates having an extended circulating serum half-life. The therapeutic conjugates comprise a therapeutic moiety linked to a half-life extension moiety via a fibroblast activation protein, alpha (FAP?)-cleavable linker. Methods of using the therapeutic conjugates are also provided.

Abstract: Disclosed herein are therapeutic conjugates having an extended circulating serum half-life. The therapeutic conjugates comprise a drug moiety linked to a half-life extension moiety via an enzyme-cleavable linker. Methods of using the therapeutic conjugates are also provided.

Abstract: Provided herein, in some embodiments, are recombinantly engineered variant of stefin polypeptides (AFFIMER® polypeptides) that binds to human serum albumin and extends the half-life of the polypeptides. Also provided herein, in some embodiments, are composition containing the polypeptides, methods of using the polypeptides, and methods of producing the polypeptides.

Abstract: Provided herein, in some embodiments, are fusion proteins comprising recombinantly engineered variant of stefin polypeptide (an AFFIMER® polypeptide) that binds to PD-L1 and a polypeptide that binds to human serum albumin (HSA). Also provided herein, in some embodiments, are compositions containing the fusion proteins, methods of using the fusion proteins, and methods of producing the fusion proteins.

Abstract: The present disclosure relates to proteins including PD-L1 binding affimer polypeptide sequences, gene expression constructs encoded those proteins, cells expressing those proteins, and pharmaceutical preparations of those proteins, gene expression constructs and cells and use in the treatment of various human conditions including cancer.

Abstract: The invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to 19, 21 to 25, 27 to 28, 35 to 37, 39, 41, 43 to 44, 46 to 47, 49 to 50, 52 to 53, 55 to 58, 63 to 64, 66, 68 to 82, 84 to 85, and 87 to 98 of SEQ ID NO: 1; characterised in that said polypeptide comprises one or more mutations relative to SEQ ID NO: 1 selected from the group consisting of: T51L, T51V, M65V, N32G, A59I, L38A, V20I, A40I, L38V, A12I, A12V, I16L, V20L, Q26E, E29M, T31K, N32D, N32H, T34V, T34R, T34D, T34P, A40V, Q42D, T45I, T45V, V48E, V48G, V48A, T51F, T51A, A59L, L67I, (V20I, L38A), (V20L, L38A), (V20I, L38V), (V20L, L38V), (E29K, K30E, E33K), (Y54D, T83D, Q86E), (A59L, G60N, D61G, N62K), (A59V, D61N, N62K), (G60N, D61G, N62K), (G60N, ?D61, N62G), ?D61, (A59L, G60N, ?D61, N62G), (A59V, G60N, D61G, N62K), (A59I, G60N, D61G, N62K), (A59I, G60N, ?D61, N62G), (A59V, G60N, ?D61, N62G), (A59V, ?D61), (G60P, ?D61, N62P),

Abstract: The invention provides novel scaffold proteins for the display of peptides such as peptide aptamers. The novel scaffold proteins are modifications of Stefin A or STM (a variant of Stefin A) and are useful as scaffold proteins and as display systems.